The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease


Cite item

Full Text

Abstract

Aim. To assess the presence of insulin resistance (IR) in non-diabetic patients with early forms of non-alcoholic fatty liver disease (NAFLD) - liver steatosis (LS) and steatohepatitis (SH) of mild activity and the influence of IR on the clinical course of these diseases. Materials and methods. 134 patients with NAFLD were examined: 54 with LS and 80 with SH. The control group consisted of 37 healthy donors. Anthropometric parameters (body mass index (BMI), waist circumference (WC)), clinical and biochemical blood indices, including the blood level of cytokeratin-18 fragments (CK-18), TNF-α and IL-6 cytokines, insulin were evaluated. The HOMA index and the fibrosis index (NAFLD FS) were calculated. Patients were divided into groups: I - with the absence of IR (HOMA-index <2.7), II - with the presence of IR (HOMA-index> 2.7). Results and discussion. Indicators of hepatic injury, inflammation, cholestasis, fibrosis and atherogenic dyslipidemia are higher in patients with LS of group II (with IR) than in group I patients (without IR). BMI, WC, γ-glutamil transpeptidase, CK-18 and fibrosis index are significantly higher in group II patients with SH compared with group I, there is no significant difference in the level of cytolysis, inflammation and dyslipidemia indices. A high incidence of IR in non-diabetic patients with LS (37.0%) and SH (55.0%) was found and the effect of IR on the clinical course of these diseases was revealed. Conclusion. Insulin resistance in non-diabetic patients with NAFLD was detected in SH (55.0%) with higher frequency than in LS (37.0%). In LS, IR is associated with impaired hepatic cell damage, intrahepatic cholestasis, atherogenic dyslipidemia and fibrosis. In SH, IR is combined with reliable growth in indicators of hepatocyte apoptosis, cytokine proinflammatory status and fibrosis. IR determines the progressing course of NAFLD, promoting the transformation of steatosis into steatohepatitis and steatohepatitis into fibrosis and liver cirrhosis.

About the authors

A A Shipovskaya

Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene

аспирант каф. пропедевтики внутренних болезней и гигиены Медицинского института ПетрГУ Petrozavodsk, Russia

O P Dudanova

Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene

Email: odudanova@gmail.com
д.м.н., проф., зав. каф. пропедевтики внутренних болезней и гигиены Медицинского института ПетрГУ Petrozavodsk, Russia

I V Kurbatova

The Institute of Biology - a separate subdivision of Karelian Research Centre of Russian Academy of Sciences

к.б.н., н.с. лаб. генетики ИБ КарНЦ РАН Petrozavodsk, Russia

References

  1. Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К., Цуканов В.В., Ушакова Т.И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно - поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;(6):31-41.
  2. Benedict M, Zhang X. Non - alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715-732. doi: 10.4254/wjh. v9.i16.715
  3. Byrne C.D, Targher G. Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease: Implications for Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2014;34(6):1155-1161. doi: 10.1161/atvbaha.114.303034
  4. Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. Diabetologia. 2016;59:879-884. doi: 10.1007/s00125-016-3904-9
  5. Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi L. Nonalcoholic fatty liver disease: Evolving paradigms. E World J Gastroenterol. 2017;23(36):6571-6592. doi: 10.3748/wjg. v23. i36.6571
  6. Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F. Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17(12):pii: E2082.
  7. Pasarín M, Abraldes J.G, Liguori E, Kok B, La Mura V. Intrahepatic vascular changes in non - alcoholic fatty liver disease: potential role of insulin - resistance and endothelial dysfunction. World J Gastroenterol. 2017;23(37):6777-6787. doi: 10.3748/wjg.v23.i37.6777
  8. Ройтберг Г.Е., Шархун О.О. Особенности прогрессирования поражения печени при инсулинорезистентности. Медицина. 2017;5:99-107.
  9. Jung K.Y, Cho S.Y, Kim H.J, Kim S.B, Song I.H. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J Clin Gastroenterol. 2014;48(10):883-888. doi: 10.1097/mcg.0000000000000065
  10. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non - alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. doi: 10.1111/hepr.12656
  11. Park B.H, Yoon J.M, Kim J.H, Moon J.H, Lee Y.H, Jang S.M, Kim Y.J. Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis. Yonsei Med J. 2017;58(4):756-762. doi: 10.3349/ymj.2017.58.4.756
  12. Cruz M.A, Cruz J.F, Macena L.B, de Santana D.S, Oliveira C.C, Lima S.O, Franca A.V. Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. Gastroenterol Res. 2015 Oct;8(5):260-264. doi: 10.14740/gr685w
  13. Arata M, Nakajima J, Nishimata S, Nagata T, Kawashima H. Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes. 2014;5(6):917-23. doi: 10.4239/wjd.v5.i6.917
  14. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61(1):153-60. doi: 10.1002/hep.27395
  15. Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non - alcoholic steatohepatitis. World J Gastroenterol. 2009;15(41):5193-5199. doi: 10.3748/wjg.15.5193
  16. Polyzos S.A, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Papadopoulou E, Zavos C, Terpos E. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Ann Hepatol. 2013;12(5):749-757.
  17. Angulo P, Hui J.M, Marchesini G, Bugianesi E, George J, Farrell G.C, Enders F, Saksena S, Burt A.D, Bida J.P, Lindor K, Sanderson S.O, Lenzi M, Adams L.A, Kench J, Therneay T.M, Day C.P. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854. doi: 10.1002/ hep.21496
  18. Wannamethee S.G, Shaper A.G, Lennon L, Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005 Dec;28(12):2913-2918. doi: 10.2337/diacare.28.12.2913
  19. Sattar N, Scherbakova O, Ford I, O’Reilly D.S, Stanley A, Forrest E, Macfarlane P.W, Packard C.J, Cobbe S.M, Shepherd J. The West of Scotland Coronary Prevention Study: Elevated alanine aminotransferase predicts new - onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes. 2004;53(11):2855-60. doi: 10.2337/diabetes.53.11.2855
  20. Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Carnevale R, Loffredo L, Pignatelli P, Violi F, Angelico F. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. Int J Hepatol. 2014;2014:784985. doi: 10.1155/ 2014/784985
  21. Hossain I.A, Rahman Shah M.M, Rahman M.K, Ali L. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr. 2016;10(1 Suppl 1):S25-S29. doi: 10.1016/j.dsx.2015.09.005
  22. Mankowska-Cyl A, Krintus M, Rajewski P, Sypniewska G. Gamma - glutamyltransferase activity as a surrogate biomarker of metabolic health status in young nondiabetic obese women. Biomark Med. 2017;11(5):449-457. doi: 10.2217/bmm-2016-0332
  23. Kunutsor S.K, Apekey T.A, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose - response meta - analysis. Int J Clin Pract. 2015;69(1):136-344. doi: 10.1111/ ijcp.12507
  24. Schreuder T.C, Marsman H.A, Lenicek M, van Werven J.R, Nederveen A.J, Jansen P.L, Schaap F.G. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G440-G445. doi: 10.1152/ajpgi.00322.2009
  25. Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203. doi: 10.1186/s12944-017-0572-9
  26. Bril F, Sninsky J.J, Baca A.M, Superko H.R, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber M.H, Mc Phaul M.J, Cusi K. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. J Clin Endocrinol Metab. 2016;101(2):644-52. doi: 10.1210/jc.2015-3111
  27. Siddiqui M.S, Fuchs M, Idowu M.O, Luketic V.A, Boyett S, Sargeant C, Stravitz R.T, Puri P, Matherly S, Sterling R.K, Contos M, Sanyal A.J. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000-1008.e3. doi: 10.1016/j.cgh.2014.10.008
  28. Younossi Z.M, Loomba R, Anstee Q.M, Rinella M.E, Bugianesi E, Marchesini G, Neuschwander-Tetri B.A, Serfaty L, Negro F, Caldwell S.H, Ratziu V, Corey K.E, Friedman S.L, Abdelmalek M.F, Harrison S.A, Sanyal A.J, Lavine J.E, Mathurin P, Charlton M.R, Goodman Z.D, Chalasani N.P, Kowdley K.V, George J, Lindor K. Diagnostic Modalities for Non - alcoholic Fatty Liver Disease (NAFLD), Non - alcoholic Steatohepatitis (NASH) and Associated Fibrosis. Hepatology. 2017 Dec 9 [Epub ahead of print].
  29. Gentili A, Daviddi G, De Vuono S, Ricci M.A, Di Filippo F, Alaeddin A, Mannarino M.R, Boni M, Vaudo G, Lupattelli G. Non - alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Dig Liver Dis. 2016 Aug;48(8):904-908. doi: 10.1016/j.dld.2016.04.004

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies